Methamphetamine and Violence in Illinois
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Signs and Symptoms, Biology, and Awareness in This Section
Section 3: Facts about Methamphetamine Signs and Symptoms, Biology, and Awareness In This Section: Basic Facts about Methamphetamine, Source: This information was accessed in 2011 from www.methresources.gov which now redirects to the ONDCP website (2012). Signs and Symptoms of Methamphetamine, Source: This information was accessed in 2011 from NIDA InfoFacts: Methamphetamine which is no longer available on the NIDA website. Anatomy of a Meth User, www.kci.org Methamphetamine Abuse and Addiction, National Institute on Drug Abuse (NIDA) Research Report Series http://www.nida.nih.gov/PDF/RRMetham.pdf Methamphetamine and Teens, Source: This information was accessed in 2011 from www.theantidrug.com which now redirects to www.drugfree.org. Biology, Behavior and the Brain: Methamphetamine Addiction, Source: This information was accessed in 2011 from www.nationalmethcenter.org, a website which is now disabled. Links: Frontline: The Meth Epidemic, www.pbs.org/wgbh/pages/frontline/meth/ (video) NIDA Drug Facts: Methamphetamine, www.drugabuse.gov/drugs-abuse/methamphetamine NIDA Drug of Abuse: Methamphetamine, www.drugabuse.gov/publications/drugfacts/methamphetamine Source: National Institute on Drug Abuse (NIDA) Methamphetamine Use and Risk for HIV/AIDS, Centers for Disease Control (CDC) HIV/AIDS Fact Sheet www.cdc.gov/hiv/resources/factsheets/meth.htm Technical Support Document: Toxicology/Clandestine Drug Labs: Methamphetamine, California Office of Environmental Health Hazard Assessment, Volume 1, Number 8 http://oehha.ca.gov/public_info/pdf/TSD%20Methamphetamine%20Meth%20La bs%2010'8'03.pdf Basic Facts about Methamphetamine Methamphetamine is an addictive stimulant drug that strongly activates certain systems in the brain. Methamphetamine is closely related chemically to amphetamine, but the central nervous system effects of methamphetamine are greater. -
The Neurocircuitry of Illicit Psychostimulant Addiction: Acute and Chronic Effects in Humans
Substance Abuse and Rehabilitation Dovepress open access to scientific and medical research Open Access Full Text Article R E V IEW The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans Sara B Taylor1 Abstract: Illicit psychostimulant addiction remains a significant problem worldwide, despite Candace R Lewis1 decades of research into the neural underpinnings and various treatment approaches. The purpose M Foster Olive1,2 of this review is to provide a succinct overview of the neurocircuitry involved in drug addiction, as well as the acute and chronic effects of cocaine and amphetamines within this circuitry in 1Program in Behavioral Neuroscience, 2Interdisciplinary Graduate Program humans. Investigational pharmacological treatments for illicit psychostimulant addiction are in Neuroscience, Arizona State also reviewed. Our current knowledge base clearly demonstrates that illicit psychostimulants University, Tempe, AZ, USA produce lasting adaptive neural and behavioral changes that contribute to the progression and maintenance of addiction. However, attempts at generating pharmacological treatments for psychostimulant addiction have historically focused on intervening at the level of the acute effects of these drugs. The lack of approved pharmacological treatments for psychostimulant addiction highlights the need for new treatment strategies, especially those that prevent or ameliorate the adaptive neural, cognitive, and behavioral changes caused by chronic use of this class of illicit drugs. Keywords: -
The Effects of Stimulant Medication on the Social Behavior of Children with ADHD During Times of Play Robert, Jr
Louisiana State University LSU Digital Commons LSU Doctoral Dissertations Graduate School 2002 The effects of stimulant medication on the social behavior of children with ADHD during times of play Robert, Jr. H. LaRue Louisiana State University and Agricultural and Mechanical College, [email protected] Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations Part of the Psychology Commons Recommended Citation LaRue, Robert, Jr. H., "The effects of stimulant medication on the social behavior of children with ADHD during times of play" (2002). LSU Doctoral Dissertations. 2403. https://digitalcommons.lsu.edu/gradschool_dissertations/2403 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please [email protected]. THE EFFECTS OF STIMULANT MEDICATION ON THE SOCIAL BEHAVIOR OF CHILDREN WITH ADHD DURING TIMES OF PLAY A Dissertation Submitted to the Graduate Faculty of the Louisiana State University and Agricultural and Mechanical College In partial fulfillment of the Requirements for the degree of Doctor of Philosophy in The Department of Psychology by Robert H. LaRue Jr. B.A., Rutgers University, 1995 M.A., Louisiana State University, 2000 December 2002 TABLE OF CONTENTS LIST OF TABLES . iv ABSTRACT . v CHAPTER 1 INTRODUCTION . 1 Overview of the Literature. 1 The Developmental Significance of Play. 6 The Effects of Stimulants on Play and Related Social Behavior - Basic Research. 8 The Effects of Stimulants on Related Social Behavior in Rats and Non-Human Primates. -
Australian Product Information Neupro® (Rotigotine) Transdermal Patches
AUSTRALIAN PRODUCT INFORMATION NEUPRO® (ROTIGOTINE) TRANSDERMAL PATCHES 1 NAME OF THE MEDICINE Rotigotine 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Neupro 1 mg: 5 cm2 patch containing 2.25 mg rotigotine with a nominal release rate of 1 mg rotigotine per 24 hours. Neupro 2 mg: 10 cm2 patch containing 4.5 mg rotigotine with a nominal release rate of 2 mg rotigotine per 24 hours. Neupro 3 mg: 15 cm2 patch containing 6.75 mg rotigotine with a nominal release rate of 3 mg rotigotine per 24 hours. Neupro 4 mg: 20 cm2 patch containing 9.0 mg rotigotine with a nominal release rate of 4 mg rotigotine per 24 hours. Neupro 6 mg: 30 cm2 patch containing 13.5 mg rotigotine with a nominal release rate of 6 mg rotigotine per 24 hours. Neupro 8 mg: 40 cm2 patch containing 18.0 mg rotigotine with a nominal release rate of 8 mg rotigotine per 24 hours. The active ingredient rotigotine is a white to light brownish powder. It is very slightly soluble to freely soluble in organic solvents, sparingly soluble in acidic aqueous solutions and practically insoluble in alkaline aqueous solutions. The formulation contains sodium metabisulfite. For the full list of excipients, see Section 6.1 List of Excipients. 3 PHARMACEUTICAL FORM Neupro is a thin, matrix-type transdermal patch composed of 3 layers: 1. A flexible, tan-colored backfilm that provides structural support and protection of the drug loaded adhesive layer. 2. A self-adhesive drug matrix layer. 3. A clear protective liner which is removed prior to use. -
Neupro, INN-Rotigotine
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Neupro 1 mg/24 h transdermal patch Neupro 3 mg/24 h transdermal patch 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Neupro 1 mg/24 h transdermal patch Each patch releases 1 mg of rotigotine per 24 hours. Each patch of 5 cm2 contains 2.25 mg of rotigotine. Neupro 3 mg/24 h transdermal patch Each patch releases 3 mg of rotigotine per 24 hours. Each patch of 15 cm2 contains 6.75 mg of rotigotine. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Transdermal patch. Thin, matrix-type, square-shaped with rounded edges, consisting of three layers. Neupro 1 mg/24 h transdermal patch The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 1 mg/24 h’. Neupro 3 mg/24 h transdermal patch The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 3 mg/24 h’. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Neupro is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults. 4.2 Posology and method of administration Posology The dose recommendations made are in nominal dose. A single daily dose should be initiated at 1 mg/24 h. Depending on the individual patient response, the dose may be increased in weekly increments of 1 mg/24 h to a maximum dose of 3 mg/24 h. The need for treatment continuation should be reconsidered every 6 months. Neupro is applied once a day. -
Pramipexole in Psychiatry: a Systematic Review of the Literature
Systematic Review of Pramipexole in Psychiatry Pramipexole in Psychiatry: A Systematic Review of the Literature Chris B. Aiken, M.D. ramipexole, a dopamine agonist approved for the Ptreatment of Parkinson’s disease and restless legs syndrome, has unique properties that offer therapeutic Objective: To assess the risks and benefits potential in psychiatry. It possesses both dopaminergic of pramipexole in psychiatric populations. and neuroprotective effects, making it a promising candi- Data Sources: A PubMed search was date for bipolar depression. Recent clinical studies have performed using the keywords pramipexole 1 and ropinirole, which identified 500 articles. earned it a place as a stage-5 treatment in the Texas and 2 Study Selection: All clinical studies in psychi- Canadian algorithms for bipolar I depression. Concur- atric populations were included in the primary rently, case reports from Parkinson’s disease clinics have review (24 articles). Studies involving other raised concerns about the potential for compulsive behav- populations were then reviewed to evaluate iors and sudden sleep attacks to arise during treatment potential risks and benefits not identified in the psychiatric studies. with the drug. To investigate these promises and perils, Data Extraction: Effect sizes were calculated the neurologic and psychiatric studies of pramipexole from controlled studies. Rates of intolerable side were systematically reviewed. effects and manic switching were estimated by pooled analysis of controlled and uncontrolled studies. METHOD Data Synthesis: Pramipexole has a large effect size (0.6–1.1) in the treatment of both bipolar and A PubMed literature search was performed using the unipolar depression with a low short-term rate of keywords pramipexole and ropinirole. -
Insights Into Pathophysiology of Punding Reveal Possible Treatment
Molecular Psychiatry (2010) 15, 560–573 & 2010 Nature Publishing Group All rights reserved 1359-4184/10 www.nature.com/mp PERSPECTIVE Insights into pathophysiology of punding reveal possible treatment strategies A Fasano1 and I Petrovic2 1Department of Neuroscience, Catholic University of Sacred Heart, Rome, Italy and 2Institute of Neurology CSS, School of Medicine, Belgrade, Serbia Punding is a stereotyped behavior characterized by an intense fascination with a complex, excessive, nongoal oriented, repetitive activity. Men tend to repetitively tinker with technical equipment such as radio sets, clocks, watches and car engines, the parts of which may be analyzed, arranged, sorted and cataloged but rarely put back together. Women, in contrast, incessantly sort through their handbags, tidy continuously, brush their hair or polish their nails. Punders are normally aware of the inapposite and obtuse nature of the behavior; however, despite the consequent self-injury, they do not stop such behavior. The most common causes of punding are dopaminergic replacement therapy in patients affected by Parkinson’s disease (PD) and cocaine and amphetamine use in addicts. The vast majority of information about punding comes from PD cases. A critical review of these cases shows that almost all afflicted patients (90%) were on treatment with drugs acting mainly on dopamine receptors D1 and D2, whereas only three cases were reported in association with selective D2 and D3 agonists. Epidemiological considerations and available data from animal models suggest that punding, drug-induced stereotypies, addiction and dyskinesias all share a common pathophysiological process. Punding may be related to plastic changes in the ventral and dorsal striatal structures, including the nucleus accumbens, and linked to psychomotor stimulation and reward mechanisms. -
Research Issues 26
If you have issues viewing or accessing this file contact us at NCJRS.gov. Research Issues --2 Guide to Drug Abuse Research Terminology u.s. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration Notional Inslitute on Drug Abuse L....t___________ ---""' ______ ~,· ~---". • RESEARCH ISSUES SERIES 1. Drugs and Employment 2. Drugs and Sex 3. Drugs and Attitude Change 4. Drugs and Family/Peer Influence 5. Drugs and Pregnancy 6. Drugs and Death 7. Drugs and Addict Lifestyles 8. A Cocaine Bibliography-Nonannotated 9. Drug Themes in Science Fiction 10. Drug Themes in Fiction 11. Predicting Adolescent Drug Abuse 12. Drug Abuse Instrument Handbook 13. Data Analysis Strategies and Designs for Substance Abuse Research 14. Drugs and Personality 15. Cocaine-Summaries of Psychosocial Research 16. The Lifestyles of Nine American Cocaine Users-Summary 17. Drugs and Crime 18. Drug Users and the Criminal Justice System 19. Drugs and Psychopathology 20. Drug Users and Driving Behaviors 21. Drugs and Minorities 22. Research Issues Update, 1978. 23. I nternational Drug Use 24. Perspectives on the History of Psychoactive Substance Use 25. Use and Abuse of Amphetamine and its Substitutes 26. Guide to Drug Abuse Research Terminology 27. Guide to the Drug Research Literature 28. Assessing Marijuana Consequences: Selected Questionnaire Items 29. Drugs and the Family Cover Illustration by Sumishta Brahmin, copyright 1978. Used by permission of the artist. Further reproduction is prohibited without permission of the artist. <0' I ,'J Research Issues 26 Guide to Drug Abuse Research Terminology Edited by Jack E. Nelson 89255 U.S. -
Maine Methamphetamine Prevention Toolkit
MAINE METHAMPHETAMINE PREVENTION TOOLKIT The Maine Methamphetamine Prevention Toolkit was made possible by a grant from the Maine Department of Public Safety, Maine Drug Enforcement Agency through the U.S. Department of Justice Community Oriented Policing Services, Grant #2008-CK-WX-0500. The opinions contained herein are those of the author(s) and do not necessarily represent the official position of the U.S. Department of Justice. References to specific companies, products, or services should not be considered an endorsement of them by the author(s) or the U.S. Department of Justice. Rather, the references are illustrations to supplement discussion of the issues. For questions and information about the Toolkit, contact the Maine Methamphetamine Prevention Project at 621-8118. June 2011 Revised September 2012 MAINE METHAMPHETAMINE PREVENTION TOOLKIT The Toolkit is an early intervention and prevention strategy for Maine communities. While methamphetamine is not currently a significant drug threat in Maine, other states have reported that widespread use and production of methamphetamine developed overnight. The Toolkit is designed to raise awareness about methamphetamine production and use, and to provide prevention, intervention and public safety resources. The Maine Methamphetamine Prevention Toolkit was made possible by a grant from the Maine Department of Public Safety, Maine Drug Enforcement Agency through the U.S. Department of Justice Community Oriented Policing Services, Grant #2008-CK-WX-0500. The opinions contained herein are those of the author(s) and do not necessarily represent the official position of the U.S. Department of Justice. References to specific companies, products, or services should not be considered an endorsement of them by the author(s) or the U.S.